News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,861 Results
Type
Article (35470)
Company Profile (357)
Press Release (453034)
Multimedia
Podcasts (74)
Webinars (9)
Section
Business (142415)
Career Advice (1023)
Deals (25221)
Drug Delivery (76)
Drug Development (67297)
Employer Resources (95)
FDA (11841)
Job Trends (10190)
News (246843)
Policy (21227)
Tag
Academia (1995)
Academic (1)
Accelerated approval (5)
Adcomms (17)
Allergies (69)
Alliances (36743)
ALS (81)
Alzheimer's disease (1184)
Antibody-drug conjugate (ADC) (120)
Approvals (11838)
Artificial intelligence (228)
Autoimmune disease (24)
Automation (12)
Bankruptcy (212)
Best Places to Work (8562)
BIOSECURE Act (13)
Biosimilars (83)
Biotechnology (287)
Bladder cancer (74)
Brain cancer (25)
Breast cancer (234)
Cancer (2036)
Cardiovascular disease (166)
Career advice (854)
Career pathing (13)
CAR-T (149)
Cell therapy (428)
Cervical cancer (15)
Clinical research (54477)
Collaboration (766)
Compensation (352)
Complete response letters (20)
COVID-19 (1983)
CRISPR (48)
C-suite (213)
Cystic fibrosis (104)
Data (2015)
Denatured (19)
Depression (46)
Diabetes (209)
Diagnostics (4864)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (29)
Drug discovery (123)
Drug pricing (61)
Drug shortages (13)
Duchenne muscular dystrophy (100)
Earnings (58780)
Editorial (33)
Employer branding (16)
Employer resources (88)
Events (74883)
Executive appointments (601)
FDA (12878)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (670)
Gene editing (119)
Generative AI (23)
Gene therapy (353)
GLP-1 (557)
Government (2635)
Grass and pollen (3)
Guidances (59)
Healthcare (13099)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (116)
Indications (28)
Infectious disease (2096)
Inflammatory bowel disease (129)
Inflation Reduction Act (10)
Influenza (37)
Intellectual property (86)
Interviews (166)
IPO (12814)
IRA (21)
Job creations (2082)
Job search strategy (737)
Kidney cancer (9)
Labor market (15)
Layoffs (388)
Leadership (10)
Legal (4684)
Liver cancer (57)
Lung cancer (285)
Lymphoma (136)
Machine learning (4)
Management (27)
Manufacturing (228)
MASH (61)
Medical device (7527)
Medtech (7531)
Mergers & acquisitions (12922)
Metabolic disorders (569)
Multiple sclerosis (73)
NASH (17)
Neurodegenerative disease (91)
Neuropsychiatric disorders (28)
Neuroscience (1698)
NextGen: Class of 2025 (4037)
Non-profit (2707)
Now hiring (25)
Obesity (302)
Opinion (198)
Ovarian cancer (68)
Pain (61)
Pancreatic cancer (68)
Parkinson's disease (139)
Partnered (16)
Patents (197)
Patient recruitment (103)
Peanut (42)
People (41297)
Pharmaceutical (59)
Pharmacy benefit managers (15)
Phase I (18158)
Phase II (24442)
Phase III (17248)
Pipeline (1136)
Policy (89)
Postmarket research (1616)
Preclinical (7716)
Press Release (71)
Prostate cancer (92)
Psychedelics (37)
Radiopharmaceuticals (248)
Rare diseases (397)
Real estate (3229)
Recruiting (37)
Regulatory (15620)
Reports (25)
Research institute (1919)
Resumes & cover letters (175)
Rett syndrome (5)
RNA editing (5)
RSV (27)
Schizophrenia (69)
Series A (124)
Series B (77)
Service/supplier (5)
Sickle cell disease (58)
Special edition (11)
Spinal muscular atrophy (158)
Sponsored (29)
Startups (2826)
State (1)
Stomach cancer (11)
Supply chain (39)
Tariffs (21)
The Weekly (54)
Vaccines (533)
Venture capitalists (36)
Weight loss (194)
Women's health (21)
Worklife (6)
Date
Today (4)
Last 7 days (748)
Last 30 days (2085)
Last 365 days (27899)
2025 (9132)
2024 (29905)
2023 (33570)
2022 (42079)
2021 (44880)
2020 (40598)
2019 (31455)
2018 (23738)
2017 (24626)
2016 (22624)
2015 (26613)
2014 (19679)
2013 (22832)
2012 (16073)
2011 (16493)
2010 (15280)
Location
Africa (493)
Alabama (52)
Alaska (4)
Arizona (117)
Arkansas (6)
Asia (29991)
Australia (5162)
California (5282)
Canada (1685)
China (463)
Colorado (202)
Connecticut (239)
Delaware (136)
Europe (68792)
Florida (704)
Georgia (159)
Idaho (40)
Illinois (386)
India (23)
Indiana (211)
Iowa (7)
Japan (131)
Kansas (78)
Kentucky (21)
Louisiana (9)
Maine (44)
Maryland (707)
Massachusetts (4054)
Michigan (181)
Minnesota (250)
Mississippi (2)
Missouri (60)
Montana (22)
Nebraska (12)
Nevada (49)
New Hampshire (39)
New Jersey (1499)
New Mexico (19)
New York (1463)
North Carolina (793)
North Dakota (8)
Northern California (2325)
Ohio (160)
Oklahoma (9)
Oregon (29)
Pennsylvania (1111)
Puerto Rico (9)
Rhode Island (25)
South America (669)
South Carolina (11)
South Dakota (1)
Southern California (1965)
Tennessee (52)
Texas (715)
United States (19183)
Utah (154)
Virginia (114)
Washington D.C. (45)
Washington State (511)
West Virginia (3)
Wisconsin (40)
488,861 Results for "libella gene therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Cell and Gene Therapy Sector Enters ‘Critical’ Period After Marks’ FDA Exit
As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene therapy space, experts express wariness over the unknowns and optimism that Marks’ legacy will carry on.
April 28, 2025
·
7 min read
·
Heather McKenzie
Gene therapy
Pfizer Axes Beqvez Worldwide, Pivoting Away From Gene Therapy for Hemophilia
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
February 21, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Tenaya Slashes a Third of Workforce To Fund Development of Cardio Gene Therapies
The layoffs will take place throughout 2025 and will mostly affect Tenaya’s research and manufacturing operations. The company is continuing to test its hypertrophic cardiomyopathy gene therapy.
April 1, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Vertex Severs Liver Gene Therapies Partnership With Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies together.
February 27, 2025
·
2 min read
·
Dan Samorodnitsky
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.
March 31, 2025
·
5 min read
·
BioSpace Insights
In partnership with GenScript
Beyond the Breakthrough: Industry Leaders Address Key Hurdles Facing Cell and Gene Therapies
At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ongoing challenges in manufacturing, distribution, treatment center capacity, and global payment structures for cell and gene therapies.
April 14, 2025
·
6 min read
·
BioSpace Insights
Gene Therapy
Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies
After a patient taking the Duchenne muscular dystrophy gene therapy Elevydis died of liver injury, Sarepta will update the label to reflect the safety signal.
March 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Dyno Therapeutics to Present Breakthrough Data on AAV Gene Delivery to the CNS, Eye, and Muscle at the 28th Annual Meeting of the American Society of Gene & Cell Therapy
April 28, 2025
·
3 min read
Gene editing
Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’
The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.
March 18, 2025
·
4 min read
·
Dan Samorodnitsky
Gene therapy
Lexeo Plots Pivotal Path for Friedreich’s Ataxia Gene Therapy After ‘Compelling’ Phase I/II Data
Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia cardiomyopathy.
April 8, 2025
·
2 min read
·
Tristan Manalac
1 of 48,887
Next
